(Reuters) — James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal. This time he’d like to buy a company with an established U.S. sales force to accelerate the group’s ambitions as it develops specialized lung drugs that are […]
Respiratory
Monaghan Medical touts Aerobika study
Monaghan Medical yesterday touted data from a 6-month retrospective study showing that its Aerobika device reduced drug use for treatment of chronic obstructive pulmonary device. The Syracuse, N.Y.-based company says its oscillating positive expiratory pressure therapy device is designed to expand the airways, help expel mucus to the upper airways and aid in drug deposition. The […]
Sunovion, medical society ally for COPD drug-delivery survey
Sunovion Pharmaceuticals and the American College of Chest Physicians yesterday launched a strategic initiative called Delivery Makes a Difference to better understand patient and healthcare provider practices in COPD therapy. A series of “nationally recognized COPD thought leaders” came together to be a part of the steering committee for the initiative. They developed a survey for 1,000 […]
Mylan, Theravance touts Phase III data for COPD drug
Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) said today that revefenacin, the 1st nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease, demonstrated positive results in 2 replicate phase III efficacy studies. Data from more than 1,250 moderate to severe COPD patients showed that both studies met their efficacy and safety endpoints. Revefenacin […]
Aerogen touts study of Solo vibrating mesh for aerosol drug delivery
Aerogen today touted results from a study showing a 32% reduction in hospital admissions when patients were treated using its Solo vibrating mesh aerosol drug delivery system, compared to a small-volume nebulizer. The Chicago-based company’s vibrating mesh is used to treat respiratory disorders such as COPD, asthma, or influenza, all of which are exacerbated in the […]
OptiNose touts Phase III data for exhaled breath drug delivery
OptiNose touted data from a pair of Phase III clinical trials proving the safety and efficacy of its exhaled breath drug delivery treatment for chronic rhinosinusitis patients with and without polyps. The company presented the data today at the American Rhinologic Society’s annual meeting in San Diego. Data from both trials showed limited adverse effects from […]
Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath. When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along […]
Boehringer Ingelheim, Qualcomm team on connected inhaler
Boehringer Ingelheim Pharmaceuticals and Qualcomm (NSDQ:QCOM) subsidiary Qualcomm Life yesterday said they’re partnering to create an inhaler that can track user information, hoping to improve outcomes for chronic obstructive pulmonary disease. Boehringer tapped Qualcomm to create a low-power, disposable module for Boehringer’s Respimat inhaler, using Qualcomm’s 2net Design platform to build a wireless communication component into the inhaler. The […]
